COVIDHIELD Will send raw material urgently required to manufacture Covishield: US tells India
New Delhi: The United States has identified sources of specific raw material urgently required for Indian manufacture of the Covishield vaccine that will immediately be made available for India, officials said on Sunday.
National Security Advisor Jake Sullivan spoke by phone today with National Security Advisor Ajit Doval when the information was revealed by the US official.
Sullivan also expressed his deep sympathy for the people of India following the recent spike in COVID-19 cases.
Sullivan affirmed America’s solidarity with India, the two countries with the greatest number of COVID-19 cases in the world.
"Building on the seven-decade health partnership between the United States and India —including battles against smallpox, polio, and HIV — they resolved that India and the United States will continue to fight the global COVID-19 pandemic together," read an official statement issued by the White House.
Just as India sent assistance to the United States as our hospitals were strained early in the pandemic, the United States is determined to help India in its time of need, the White House said.
"To this end, the United States is working around the clock to deploy available resources and supplies. The United States has identified sources of specific raw material urgently required for Indian manufacture of the Covishield vaccine that will immediately be made available for India. To help treat COVID-19 patients and protect front-line health workers in India, the United States has identified supplies of therapeutics, rapid diagnostic test kits, ventilators, and Personal Protective Equipment (PPE) that will immediately be made available for India," read the statement.
"The United States also is pursuing options to provide oxygen generation and related supplies on an urgent basis. The U.S. Development Finance Corporation (DFC) is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India, enabling BioE to ramp up to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022. Additionally, the United States is deploying an expert team of public health advisors from the Center for Disease Control (CDC) and USAID to work in close collaboration with the U.S. Embassy, India’s health ministries, and India’s Epidemic Intelligence Service staff. USAID will also quickly work with CDC to support and fast-track the mobilization of emergency resources available to India through the Global Fund," the statement said.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
